Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Cross-sectional study: The use of Selective Serotonin Reuptake Inhibitors is associated with a reduction in measured movements.

14 Apr, 2022 | 08:32h | UTC

Association of Selective Serotonin Reuptake Inhibitor Use With Abnormal Physical Movement Patterns as Detected Using a Piezoelectric Accelerometer and Deep Learning in a Nationally Representative Sample of Noninstitutionalized Persons in the US – JAMA Network Open

 

Commentary on Twitter

 

RCT: Comparison of intranasal vs. intramuscular naloxone in opioid overdoses managed by ambulance staff.

14 Apr, 2022 | 08:23h | UTC

Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial – Addiction

Commentary: Breathing restored within 10 minutes for 80% of overdose patients using nasal spray – Norwegian University of Science and Technology

 

Cluster RCT: A shorter antimicrobial prophylaxis duration (less than 24 hours after surgery) is noninferior to a more extended regimen (24-48 hours) after clean orthopedic surgery.

13 Apr, 2022 | 10:56h | UTC

Effect of Antimicrobial Prophylaxis Duration on Health Care–Associated Infections After Clean Orthopedic Surgery: A Cluster Randomized Trial – JAMA Network Open

 

Commentary on Twitter

 

M-A: Sodium-glucose Cotransporter 2 inhibitors are associated with reduced risk of hyperkalemia in people with type 2 diabetes.

13 Apr, 2022 | 10:52h | UTC

Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials – Circulation

 

RCT: Dapagliflozin did not significantly improve glycemic control in children and young adults with type 2 diabetes.

13 Apr, 2022 | 10:46h | UTC

Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

 

Review | Less is more: deprescribing medications in older adults with kidney disease.

13 Apr, 2022 | 10:44h | UTC

Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360

Related:

Process evaluation of implementation strategies to reduce potentially inappropriate medication prescribing in older population: A scoping review.

AGA clinical practice update on de-prescribing of proton pump inhibitors.

Development of a metric to detect and decrease low-value prescribing in older adults.

Cluster Randomized Clinical Trial: An electronic decision support system for deprescribing in hospitalized older adults was safe and led to improvements in deprescribing but did not reduce adverse drug events.

Systematic Review: Quantifying anticholinergic burden and sedative load in older adults with polypharmacy.

Deprescribing in palliative patients with cancer: a concise review of tools and guidelines.

Systematic review: Prescribing practices, patterns, and potential harms in patients receiving palliative care – “many patients receiving palliative care receive multiple medications closer to the time of death”.

A narrative review of evidence to guide deprescribing among older adults.

Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens.

Polypharmacy Management in Older Patients – Mayo Clinic Proceedings

Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy – Deutsches Ärzteblatt internationa

Eliminating Medication Overload: A National Action Plan

Deprescribing in Older Adults With Cardiovascular Disease – Journal of the American College of Cardiology

Position Statement: Reducing Inappropriate Medication Use & Polypharmacy (several articles and commentaries on the subject)

 

M-A: Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV.

13 Apr, 2022 | 10:18h | UTC

Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis – EClinicalMedicine

News Release: Protease inhibitors safer than thought for pregnant women with HIV – University of Oxford

 

Drug resistant TB – latest developments in epidemiology, diagnostics and management.

13 Apr, 2022 | 10:09h | UTC

Drug resistant TB – latest developments in epidemiology, diagnostics and management – International Journal of Infectious Diseases

Related:

Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.

WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment

Randomized Trial: 9-month Treatment for Multi-drug Resistant TB is as Effective as 24-month Treatment

Canadian Tuberculosis Standards – 8th Edition.

Guideline: Treatment of Drug-Resistant Tuberculosis

NICE Guideline: Tuberculosis

The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis

Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives

 

RCT: Single-dose HPV vaccination found effective among young African women.

12 Apr, 2022 | 10:08h | UTC

Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women – NEJM Evidence

News Releases:

Study boosts support for single-dose HPV vaccine regimen – University of Washington

One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer – World Health Organization

Related:

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

 

Commentary on Twitter (thread – click for more)

 

M-A: SGLT2 inhibitors reduce hospitalizations in patients with heart failure regardless of the presence of diabetes.

12 Apr, 2022 | 10:05h | UTC

Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure: A Systematic Review and Meta-analysis – Annals of Internal Medicine (link to abstract – $ for full-text)

News Release: SGLT2 inhibitors reduces hospitalization for heart failure regardless of presence of diabetes – American College of Physicians

 

Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management.

12 Apr, 2022 | 10:02h | UTC

Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management – Seminars in Oncology

 

Aspirin for primary cardiovascular prevention in patients with diabetes: uncertainties and opportunities.

12 Apr, 2022 | 08:45h | UTC

Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities – Thrombosis and Haemostasis

Related Guideline:

USPSTF draft statement revises previous guidance and now recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults aged 60 years or older.

Related Randomized Trials:

Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease

Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes

Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

Related Meta-Analysis:

Meta-Analysis: Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events

Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups – BMC Medicine

Related Opinions:

Aspirin for Primary Prevention: Is This the End of the Road?

Evidence evolving on aspirin as prevention – ACP Internist

 

RCT: Efficacy and safety of weekly somatrogon vs. daily somatropin in children with growth hormone deficiency.

12 Apr, 2022 | 08:34h | UTC

Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study – The Journal of Clinical Endocrinology & Metabolism

 

Review: Drug-induced interstitial lung disease.

12 Apr, 2022 | 08:29h | UTC

Drug-induced interstitial lung disease – European Respiratory Review

Related: Systematic Review: Drug-Induced Interstitial Lung Disease

 

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.

12 Apr, 2022 | 08:27h | UTC

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment – ESMO Open

 

RCT: For adults with HIV, a 4-days-on and 3-days-off treatment strategy is noninferior to standard treatment for maintaining viral suppression.

11 Apr, 2022 | 01:56h | UTC

A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial – The Lancet HIV (link to abstract – $ for full-text)

Commentary: Intermittent Treatment Strategy Is Effective for HIV – Consultant360

 

Commentaries on Twitter

 

CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study.

11 Apr, 2022 | 01:40h | UTC

CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study – BMC Medicine

 

NCCN Guidelines: CAR T-cell–related toxicities in patients with cancer.

11 Apr, 2022 | 01:32h | UTC

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Related:

Reviews: CAR T-Cell Therapy Toxicities and Side Effects

Reviews: CAR T-Cell Therapy Toxicities and Side Effects

Critical Care Management of Chimeric Antigen Receptor T Cell–related Toxicity. Be Aware and Prepared

Reviews: CAR T-Cell Therapy Toxicities and Side Effects

 

RCT: Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough.

11 Apr, 2022 | 01:22h | UTC

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 

M-A: Interventions to reduce opioid prescriptions following urological surgery.

11 Apr, 2022 | 00:42h | UTC

Interventions to Reduce Opioid Prescriptions following Urological Surgery: A Systematic Review and Meta-Analysis – The Journal of Urology

 

Cohort Study: Use of Phosphodiesterase 5 Inhibitors linked to increased risk of ocular adverse events.

8 Apr, 2022 | 11:04h | UTC

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US – JAMA Ophthalmology (free for a limited period)

News Release: U.S. insurance claims show strong link between ED medications and vision problems – University of British Columbia

Commentaries:

Phase 4 Studies on Phosphodiesterase 5 Inhibitors – JAMA Ophthalmology (free for a limited period)

Expert reaction to study looking at risk of vision impairment and loss, and use of phosphodiesterase type 5 inhibitors – Science Media Centre

Could Viagra, Cialis Raise Men’s Odds for Eye Trouble? – HealthDay

 

M-A: Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia.

8 Apr, 2022 | 10:50h | UTC

Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis – International Journal of Infectious Diseases

Related:

Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

Review: Vaccine-induced immune thrombotic thrombocytopenia.

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

M-A: Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization.

7 Apr, 2022 | 09:55h | UTC

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: Common Antidepressant Likely Cuts Risk Of Covid Hospitalization, Study Finds – Forbes

Related:

Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Commentary on Twitter

 

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

7 Apr, 2022 | 10:00h | UTC

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Related:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter (thread – click for more)

 

RCT: Among patients with complicated urinary tract infection, oral Tebipenem Pivoxil Hydrobromide was noninferior to intravenous Ertapenem and showed a similar safety profile.

7 Apr, 2022 | 09:53h | UTC

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.